{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-24-000036","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.279859+00:00","generated_at":"2026-06-02T18:40:30.748020+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Caribou Q1 net loss $41.2M; cash $345.9M; IND cleared for CB-010 in lupus","bullets":["Net loss of $41.2M for Q1 2024 vs $28.0M in Q1 2023; R&D expenses rose to $33.8M.","Cash, cash equivalents, and marketable securities $345.9M as of Mar 31, 2024, funding operations into Q1 2026.","FDA IND clearance for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 trial expected to start by YE 2024.","Plans to present initial CB-010 dose expansion data at ASCO June 3, 2024; initial CB-011 data by YE 2024.","Licensing and collaboration revenue $2.4M, down from $3.5M due to terminated AbbVie agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-24-000036","json":"https://secwatch.observer/filing/0001619856-24-000036.json","markdown":"https://secwatch.observer/filing/0001619856-24-000036.md","text":"https://secwatch.observer/filing/0001619856-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000036/0001619856-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000036/crbu-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:40:30.748020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46f4d6c9e712e3b6574c999afd5644a9510e8160","claim":"Caribou Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $2.4 million.","evidence_excerpt":"Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $2.4 million for the three months ended March 31, 2024, compared to $3.5 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000036/0001619856-24-000036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$2.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}